ストックスクリーナーアプリを入手
106.60
2.01%
2.10
前日終値:
$104.50
開ける：
$103.28
24時間の取引高:
149.26K
Relative Volume:
0.85
時価総額：
$714.12M
収益：
-
当期純損益:
$-14.99M
株価収益率:
-51.58
EPS:
-2.0665
ネットキャッシュフロー:
$-10.01M
1週間 パフォーマンス:
+9.01%
1か月 パフォーマンス:
+79.40%
6か月 パフォーマンス:
+69.21%
1年 パフォーマンス:
+178.62%
1日の値動き範囲:
$97.97
$107.41
1週間の範囲:
$88.33
$112.57
52週間の値動き範囲:
$29.18
$112.57
Monopar Therapeutics Inc Stock (MNPR) Company Profile
名前
Monopar Therapeutics Inc
セクター
電話
(847) 388-0349
住所
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
106.60 | 714.12M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-09 | 開始されました | Morgan Stanley | Overweight |
| 2025-11-14 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | 開始されました | Leerink Partners | Outperform |
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-09-09 | 開始されました | BTIG Research | Buy |
| 2025-09-03 | 開始されました | Oppenheimer | Outperform |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-08-26 | 再開されました | H.C. Wainwright | Buy |
| 2025-07-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-06-23 | 開始されました | Chardan Capital Markets | Buy |
| 2025-03-19 | 再開されました | Piper Sandler | Overweight |
| 2025-01-10 | 開始されました | Piper Sandler | Overweight |
| 2024-10-11 | 開始されました | Rodman & Renshaw | Buy |
| 2021-01-28 | 開始されました | ROTH Capital | Buy |
すべてを表示
Monopar Therapeutics Inc (MNPR) 最新ニュース
MNPR (MNPR): Arthur Klausner files Form 144/A to sell 5,000 shares - Stock Titan
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT - RTTNews
Monopar Therapeutics shares gain about 9.5% after immediate support holds above $100.45 - Traders Union
What's behind Monopar Therapeutics's latest 11.6% stock surge? - Traders Union
Form 144 Monopar Therapeutics Inc. For: 7 July By Investing.com - Investing.com Nigeria
MNPR stock. Monopar Therapeutics stays tied to its clinical pipeline. - ad-hoc-news.de
Enterprise value to EBIT forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Monopar Therapeutics: ALXN1840's Bull Case Has Improved (NASDAQ:MNPR) - Seeking Alpha
Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Monopar Therapeutics (MNPR) CFO nets shares from RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics (MNPR) CEO nets shares after RSU vesting and tax withholding - Stock Titan
Monopar Therapeutics (MNPR) COO gains stock via RSU vesting and tax withholding - Stock Titan
Liquidity Mapping Around (MNPR) Price Events - Stock Traders Daily
Monopar Therapeutics price target raised to $117 from $104 at BTIG - TipRanks
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Maintains Target Price $117 - Moomoo
MNPR Q1 2026 Earnings: Significant EPS Beat Highlights Progress in Clinical PipelineDiluted EPS Report - dars.gov.et
Form 4 Monopar Therapeutics Inc For: 30 June By Investing.com - Investing.com Nigeria
MNPR Maintained by BTIG -- Price Target Raised to $117 - GuruFocus
Monopar Therapeutics (MNPR) director granted 1,284 stock options - Stock Titan
Monopar Therapeutics (MNPR) director Nicole Sweeny files initial Form 3 - Stock Titan
Monopar gets rare pediatric disease tag for Wilson treatment - Investing.com UK
Monopar Therapeutics (MNPR) Receives FDA Rare Pediatric Disease Designation - GuruFocus
Monopar Therapeutics Inc. Granted FDA Rare Pediatric Disease Designation – Official SEC 8-K Filing June 30, 2026 - Minichart
BTIG Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $117 - Moomoo
Monopar Wins FDA Rare Pediatric Disease Designation - TipRanks
Monopar stock jumps after FDA rare pediatric disease tag By Investing.com - Investing.com India
Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease - The Manila Times
FDA grants Rare Pediatric Disease designation to Monopar (MNPR) Wilson disease drug ALXN1840 - Stock Titan
FDA rare pediatric disease tag could speed ALXN1840’s path for Wilson disease - Stock Titan
BTIG raises Monopar Therapeutics price target on regulatory outlook - Investing.com
BTIG raises Monopar Therapeutics price target on regulatory outlook By Investing.com - Investing.com Canada
+8.47% for Monopar Therapeutics stock as buyers push price above key averages - Traders Union
Monopar Therapeutics Inc Actuals & Estimates (NASDAQ:MNPR) - TradingView
H.C. Wainwright reiterates Monopar stock rating on trial data By Investing.com - Investing.com India
Companies Like Monopar Therapeutics (NASDAQ:MNPR) Can Afford To Invest In Growth - Moomoo
Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to Russell 2000 Value Benchmark - marketscreener.com
H.C. Wainwright reiterates Monopar stock rating on trial data - Investing.com UK
Monopar Therapeutics Inc.(NasdaqCM:MNPR) added to Russell Microcap Value Benchmark Index - marketscreener.com
MNPR Reiterates by HC Wainwright & Co. -- Price Target Maintained at $105 - GuruFocus
Monopar Therapeutics Insiders Make Handsome Sum Selling Stock At US$67.15 Per Share - simplywall.st
Price to earnings forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Price to book forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Enterprise value to EBITDA forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Enterprise value to revenue forward of Monopar Therapeutics Inc. – NASDAQ:MNPR - TradingView
Monopar Therapeutics Inc.(NasdaqCM: MNPR) added to Russell 3000E Value Benchmark - marketscreener.com
Enterprise value to revenue forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Price to sales forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Price to earnings forward of Monopar Therapeutics Inc – GETTEX:1IY0 - TradingView
Monopar plans mid-2026 NDA filing for Wilson disease drug - Investing.com UK
Monopar Therapeutics Inc (MNPR) 財務データ
収益
当期純利益
現金流量
EPS
Monopar Therapeutics Inc (MNPR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Vu Quan Anh | Chief Financial Officer |
Dec 26 '25 |
Buy |
69.95 |
1,500 |
104,925 |
1,500 |
2.64%
大文字化:
|
ボリューム (24 時間):